Drug: abatacept (DrugBank: Abatacept)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 63 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04255134 (ClinicalTrials.gov) | September 7, 2020 | 14/11/2019 | Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) | Comparison of Abatacept With Tumor Necrosis Factor Inhibitors in the Treatment of Rheumatoid Arthritis Pain: A Phase IV Trial | Rheumatoid Arthritis | Drug: Abatacept Injection;Drug: Adalimumab Injection | St George's, University of London | NULL | Recruiting | 18 Years | 75 Years | All | 60 | Phase 4 | United Kingdom |
| 2 | NCT04529863 (ClinicalTrials.gov) | August 17, 2020 | 25/8/2020 | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tocilizumab vs Abatacept | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines- Tocilizumab vs Abatacept | Rheumatoid Arthritis | Drug: Tocilizumab;Drug: Abatacept | Brigham and Women's Hospital | Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging Intramural Research Program (IRP);Rutgers University;Johns Hopkins University | Active, not recruiting | 18 Years | N/A | All | 30432 | United States | |
| 3 | NCT04529902 (ClinicalTrials.gov) | August 17, 2020 | 25/8/2020 | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - (DREAM) TNFi vs Abatacept | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - Tumor Necrosis Factor Inhibitors vs Abatacept | Rheumatoid Arthritis | Drug: Tumor Necrosis Factor Inhibitors;Drug: Abatacept | Brigham and Women's Hospital | Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging Intramural Research Program (IRP);Rutgers University;Johns Hopkins University | Active, not recruiting | 18 Years | N/A | All | 66026 | United States | |
| 4 | NCT04529876 (ClinicalTrials.gov) | August 17, 2020 | 25/8/2020 | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept | Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines - Tofacitinib vs Abatacept | Rheumatoid Arthritis | Drug: Tofacitinib;Drug: Abatacept | Brigham and Women's Hospital | Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging Intramural Research Program (IRP);Rutgers University;Johns Hopkins University | Active, not recruiting | 18 Years | N/A | All | 29464 | United States | |
| 5 | NCT04186871 (ClinicalTrials.gov) | January 7, 2020 | 28/11/2019 | Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis | A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis | Autoimmune Disorder;Rheumatoid Arthritis;Systemic Lupus Erythematosus;Primary Sjögren's Syndrome | Drug: branebrutinib;Drug: abatacept;Drug: branebrutinib placebo | Bristol-Myers Squibb | NULL | Recruiting | 18 Years | 65 Years | All | 185 | Phase 2 | United States;Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT04120831 (ClinicalTrials.gov) | October 7, 2019 | 4/10/2019 | TOLERA: Tolerance Enhancement in RA | Sequential B Cell/T Cell Therapy to Re-induce Humoral Immune TOLErance in ACPA- Positive Rheumatoid Arthritis A Prospective, Randomized Controlled Open Label Single-centre Clinical Trial in Adult Subjects With Active ACPA-positive Rheumatoid Arthritis Failing Methotrexate | Rheumatoid Arthritis | Drug: Abatacept Injection | University of Erlangen-Nürnberg Medical School | NULL | Recruiting | 18 Years | N/A | All | 20 | Phase 2 | Germany |
| 7 | NCT03619876 (ClinicalTrials.gov) | July 10, 2019 | 3/8/2018 | Effects of Abatacept on Myocarditis in Rheumatoid Arthritis | Effects of Abatacept on Myocarditis in Rheumatoid Arthritis | Rheumatoid Arthritis;Myocardial Inflammation | Drug: Abatacept;Drug: Adalimumab | Columbia University | Bristol-Myers Squibb | Recruiting | 18 Years | N/A | All | 20 | Phase 4 | United States |
| 8 | NCT03652961 (ClinicalTrials.gov) | June 2, 2019 | 23/8/2018 | Rheumatoid Arthritis Memory B Cells and Abatacept (RAMBA) | Rheumatoid Arthritis Memory B Cells and Abatacept (RAMBA) | Rheumatoid Arthritis | Drug: Abatacept | NYU Langone Health | Dartmouth-Hitchcock Medical Center | Recruiting | 18 Years | N/A | All | 25 | Phase 4 | United States |
| 9 | NCT03882008 (ClinicalTrials.gov) | May 23, 2019 | 7/11/2018 | A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis | Phase IV Open-Label Study to Evaluate Biomarkers to Predict the Efficacy of Abatacept in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Abatacept | University of Washington | Bristol-Myers Squibb | Enrolling by invitation | 18 Years | N/A | All | 25 | Phase 4 | United States |
| 10 | NCT03669367 (ClinicalTrials.gov) | April 1, 2019 | 26/7/2018 | EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study) | EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA) | Palindromic Rheumatism, Wrist | Drug: Abatacept Injection;Drug: hydroxycloroquina | Fundacion Clinic per a la Recerca Biomédica | NULL | Not yet recruiting | 18 Years | N/A | All | 98 | Phase 4 | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT03700021 (ClinicalTrials.gov) | April 2019 | 2/10/2018 | Response to Treatment With Intravenous Abatacept Adults With Rheumatoid Arthritis | Single-Open Label Study to Assess Changes in the Immune Profile in Response to Treatment With Intravenous Abatacept Adults With Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs | Rheumatoid Arthritis | Drug: Abatacept + csDMARD | New York University School of Medicine | NULL | Not yet recruiting | 18 Years | N/A | All | 25 | Phase 4 | United States |
| 12 | NCT03784261 (ClinicalTrials.gov) | December 17, 2018 | 17/12/2018 | Usefulness of Non TNF Usage in RA Patients | Usefulness of Non TNF Usage in Rheumatoid Arthritis Patients | Rheumatoid Arthritis | Drug: Drug: Salirumab;Drug: Drug: Tocilizmab;Drug: Drug: Abatacept | Shinshu University | NULL | Recruiting | 20 Years | 100 Years | All | 90 | Phase 2 | Japan |
| 13 | NCT03714022 (ClinicalTrials.gov) | November 9, 2018 | 18/10/2018 | A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes | A Randomized, Open-Label, Parallel-Group, Single-dose, Biocomparability Study of the Pharmacokinetics of the Abatacept (BMS-188667) Drug Product Converted From Drug Substance of a New Abatacept Drug Substance Process Relative to the Current Abatacept Drug Process in Healthy Participants | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | 55 Years | All | 140 | Phase 1 | United States |
| 14 | NCT03084419 (ClinicalTrials.gov) | June 26, 2018 | 7/3/2017 | APRIL (AbatacePt in Rheumatoid Arthritis-ILD) | Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease: A Feasibility Trial | Rheumatoid Arthritis;Interstitial Lung Disease | Drug: Abatacept | Cambridge University Hospitals NHS Foundation Trust | Bristol-Myers Squibb | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | United Kingdom |
| 15 | NCT03492658 (ClinicalTrials.gov) | May 17, 2018 | 3/4/2018 | Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA) | Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA). | Rheumatoid Arthritis;Rheumatic Diseases | Drug: Abatacept;Drug: Methotrexate | Leiden University Medical Center | NULL | Recruiting | 18 Years | N/A | All | 46 | Phase 4 | Netherlands |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT03227419 (ClinicalTrials.gov) | January 22, 2018 | 19/7/2017 | Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders | Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial | Arthritis, Rheumatoid | Drug: Tocilizumab Prefilled Syringe;Drug: Abatacept Prefilled Syringe | Lille Catholic University | NULL | Recruiting | 18 Years | N/A | All | 224 | Phase 4 | France |
| 17 | NCT03457792 (ClinicalTrials.gov) | December 19, 2017 | 13/2/2018 | A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis | Abatacept in Early-Stage Rheumatoid Arthritis Patients: Longterm Experience and Efficacy in Routine Clinical Practice | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Recruiting | 18 Years | N/A | All | 400 | Germany | |
| 18 | NCT03440892 (ClinicalTrials.gov) | November 1, 2017 | 14/2/2018 | Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients | Longitudinal Observational Study on Rheumatoid Arthritis Patients: Effects of Antirheumatic Treatment on Serum Levels of Survivin | Rheumatoid Arthritis | Drug: methotrexate;Drug: sulfasalazine;Drug: abatacept;Drug: tocilizumab;Drug: tofacitinib/baricitinib | Vastra Gotaland Region | NULL | Recruiting | 20 Years | N/A | All | 2500 | Sweden | |
| 19 | NCT03188081 (ClinicalTrials.gov) | August 4, 2017 | 12/6/2017 | A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept | A Prospective, Multicentric, Observational Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life RA Patients Treated With Abatacept SC | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Recruiting | 18 Years | N/A | All | 300 | Italy | |
| 20 | NCT03086343 (ClinicalTrials.gov) | May 9, 2017 | 20/3/2017 | A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs | A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs) | Rheumatoid Arthritis (RA) | Drug: Abatacept;Drug: Placebo for abatacept;Drug: Upadacitinib;Drug: Placebo for upadacitinib | AbbVie | NULL | Active, not recruiting | 18 Years | N/A | All | 613 | Phase 3 | United States;Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Czechia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;Chile;Colombia |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT02805010 (ClinicalTrials.gov) | October 2016 | 12/6/2016 | Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously | A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects | Rheumatoid Arthritis (RA) | Drug: Abatacept;Other: Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Bristol-Myers Squibb | Active, not recruiting | 18 Years | 45 Years | Both | 22 | Phase 1 | NULL |
| 22 | NCT02037737 (ClinicalTrials.gov) | September 30, 2016 | 21/11/2013 | Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting | Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting in Patients With Inadequate Response to One or Several Conventional DMARDs Including Methotrexate in France. A Database Analysis Based on the ACTION Study | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 153 | NULL | |
| 23 | NCT02547493 (ClinicalTrials.gov) | March 3, 2016 | 7/9/2015 | Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients | Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept | Rheumatoid Arthritis | Biological: pneumococcal polysaccharide vaccine;Biological: pneumococcal conjugate vaccine;Drug: Abatacept | University Hospital, Montpellier | Bristol-Myers Squibb | Active, not recruiting | 18 Years | 85 Years | All | 80 | N/A | France;Monaco |
| 24 | NCT02652273 (ClinicalTrials.gov) | January 2016 | 8/1/2016 | Inhibition of Co-Stimulation in Rheumatoid Arthritis | Inhibition of Co-Stimulation in Rheumatoid Arthritis | Arthritis, Rheumatoid | Drug: Abatacept | NHS Greater Glasgow and Clyde | University of Glasgow | Not yet recruiting | 18 Years | N/A | Both | 25 | Phase 4 | United Kingdom |
| 25 | NCT02557100 (ClinicalTrials.gov) | November 19, 2015 | 4/9/2015 | Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis | A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs | Rheumatoid Arthritis | Drug: Abatacept;Drug: Adalimumab;Drug: Methotrexate | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 80 | Phase 4 | United States;Canada;Mexico;Algeria |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | NCT02504268 (ClinicalTrials.gov) | August 31, 2015 | 20/7/2015 | Effects of Abatacept in Patients With Early Rheumatoid Arthritis | A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive | Rheumatoid Arthritis | Drug: Abatacept;Drug: Methotrexate;Other: Abatacept Placebo;Other: Methotrexate Placebo | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 1067 | Phase 3 | United States;Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Singapore;South Africa;Spain;Sweden;Taiwan;United Kingdom;Czech Republic;Puerto Rico;Saudi Arabia;United Arab Emirates |
| 27 | NCT02598466 (ClinicalTrials.gov) | July 2015 | 4/11/2015 | Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa | Patient-Reported Efficacy of Subcutaneous Abatacept in Rheumatoid Arthritis: An Evaluation Of Patients In a Compassionate Use Programme in South Africa | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | Hexor, South Africa | Completed | 18 Years | N/A | Both | 69 | N/A | NULL |
| 28 | NCT02353780 (ClinicalTrials.gov) | March 2015 | 30/6/2013 | Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept | Mechanistic Studies of B- and T-Cell Function in Rheumatoid Arthritis Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept | Rheumatoid Arthritis (RA) | Drug: TNF Antagonist (enbrel, humire, remicade, cimzia, symponi);Drug: Abatacept;Drug: Tocilizumab | Dr. Larry W. Moreland | Genentech, Inc.;Bristol-Myers Squibb | Terminated | 18 Years | 64 Years | All | 10 | Phase 4 | United States |
| 29 | NCT02053727 (ClinicalTrials.gov) | July 2014 | 6/11/2013 | Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background | Pilot Study to Evaluate Subcutaneous Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background- a Pilot, Double-blind, Placebo-controlled, Randomized, Controlled Trial. | Rheumatoid Arthritis;Chronic Hepatitis B | Drug: Abatacept;Drug: Placebo | University of California, Los Angeles | NULL | Withdrawn | 18 Years | N/A | All | 0 | N/A | United States |
| 30 | NCT02169544 (ClinicalTrials.gov) | January 31, 2014 | 14/5/2014 | Post-marketing Study Assessing the Long-Term Safety of Abatacept | Post-marketing Study Assessing the Long-Term Safety of Abatacept | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 100000 | N/A | NULL |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT02027298 (ClinicalTrials.gov) | November 2013 | 18/11/2013 | Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study | Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study | Primary Sjogren's Syndrome;Secondary Sjogren's Syndrome;Inflammatory Arthritis;Rheumatoid Arthritis | Drug: Abatacept | The Cleveland Clinic | Bristol-Myers Squibb | Withdrawn | 18 Years | N/A | All | 0 | Phase 2 | United States |
| 32 | NCT01890473 (ClinicalTrials.gov) | July 2013 | 27/6/2013 | Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe | Phase Ib, Multicenter, Randomized, Open-Label, Parallel-Group Study to Characterize the Pharmacokinetics of a Single Dose of Abatacept 125 mg Administered Subcutaneously Using the BD Physioject™ Autoinjector or the UltraSafe Passive Needle Guard Prefilled Syringe | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 356 | Phase 1 | United States;Argentina;Mexico;Peru;South Africa |
| 33 | NCT01844895 (ClinicalTrials.gov) | April 2013 | 5/4/2013 | Methotrexate-Inadequate Response Autoinjector Device Sub Study | Substudy-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 120 | Phase 3 | NULL |
| 34 | NCT02090556 (ClinicalTrials.gov) | January 31, 2012 | 19/2/2014 | Long-term Experience With Abatacept SC in Routine Clinical Practice | Long-term Experience With Abatacept SC in Routine Clinical Practice | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | inVentiv Health Clinical;PharmaNet | Unknown status | 18 Years | N/A | All | 2896 | Australia;Austria;France;Germany;Greece;Italy;Monaco;Netherlands;Spain;Switzerland;United Kingdom | |
| 35 | NCT01295151 (ClinicalTrials.gov) | August 2011 | 11/2/2011 | SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug. | Randomised-controlled Trial of Switching to Alternative Tumour-necrosis Factor (TNF)-Blocking Drugs or Abatacept or Rituximab in Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug | Rheumatoid Arthritis | Drug: Etanercept;Drug: Abatacept;Biological: Rituximab;Drug: Adalimumab;Drug: Certolizumab Pegol;Drug: Infliximab;Drug: Golimumab | Julia Brown | NULL | Completed | 18 Years | N/A | Both | 122 | Phase 4 | United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT01299961 (ClinicalTrials.gov) | March 2011 | 18/2/2011 | Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis | Musculoskeletal Ultrasound as a Marker of Therapeutic Response to Abatacept in Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: abatacept | University of California, Los Angeles | NULL | Completed | 18 Years | N/A | All | 25 | Phase 3 | United States |
| 37 | NCT01339481 (ClinicalTrials.gov) | February 2011 | 13/4/2011 | A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept | A Phase 0, Open-Label, Multi-Center, Observational Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept | Rheumatoid Arthritis | Drug: abatacept | Astellas Pharma Inc | Perseid Therapeutics LLC | Completed | 18 Years | N/A | Both | 26 | N/A | United States |
| 38 | NCT01142726 (ClinicalTrials.gov) | December 2010 | 3/6/2010 | Efficacy and Safety Study of Abatacept Subcutaneous Plus Methotrexate in Inducing Remission in Adults With Very Early Rheumatoid Arthritis | A Phase 3b, Randomized, Active Controlled Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults With Very Early RA | Rheumatoid Arthritis | Drug: Abatacept;Drug: Methotrexate;Drug: Abatacept placebo;Drug: Methotrexate placebo | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 511 | Phase 3 | United States;Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;Norway |
| 39 | NCT01221636 (ClinicalTrials.gov) | October 2010 | 13/10/2010 | Pharmacokinetic Study to Compare the Blood Levels of Low vs High Metal Manufacture of Abatacept | A Study to Compare the Pharmacokinetics of Abatacept (BMS-188667) Drug Product Using Active Pharmaceutical Ingredient Manufactured With a High Concentration of Metals Relative to the Active Pharmaceutical Ingredient Manufactured With a Low Concentration of Metals | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Withdrawn | 18 Years | 55 Years | Both | 0 | Phase 1 | United States |
| 40 | NCT01000441 (ClinicalTrials.gov) | December 2009 | 22/10/2009 | Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis | Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: infliximab, etanercept, adalimumab;Drug: abatacept, rituximab or tocilizumab | University Hospital, Strasbourg, France | NULL | Recruiting | 18 Years | N/A | Both | 300 | Phase 4 | France;Monaco |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT00929864 (ClinicalTrials.gov) | October 2009 | 29/6/2009 | Abatacept Versus Adalimumab Head-to-Head | A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Abatacept;Drug: Adalimumab | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 869 | Phase 3 | United States;Argentina;Canada;Chile;Peru |
| 42 | NCT00767325 (ClinicalTrials.gov) | December 2008 | 6/10/2008 | A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonography | Multi-Center, Open Label Study to Assess Early Response to Abatacept With Background Methotrexate Using Power Doppler Ultrasonography in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate | Rheumatoid Arthritis | Drug: Abatacept;Drug: Methotrexate | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 104 | Phase 3 | Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom |
| 43 | NCT02109666 (ClinicalTrials.gov) | March 2008 | 8/4/2014 | Long Term Experience With Abatacept in Routine Clinical Practice | Long Term Experience With Abatacept in Routine Clinical Practice | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 2364 | N/A | Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Spain;Switzerland |
| 44 | NCT00547521 (ClinicalTrials.gov) | December 2007 | 19/10/2007 | Phase IIIB Subcutaneous Abatacept Monotherapy Study | A Phase IIIb, Multi-center, Stratified, Open-Label Study to Evaluate the Immunogenicity, Steady State Trough Level, and Safety of Subcutaneous Abatacept (BMS-188667) in Subjects With Rheumatoid Arthritis Administered With or Without Background Methotrexate | Rheumatoid Arthritis (RA) | Drug: abatacept;Drug: Methotrexate (MTX) | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 119 | Phase 3 | United States;Australia;Mexico;South Africa;Brazil;Canada;Peru |
| 45 | NCT00533897 (ClinicalTrials.gov) | November 2007 | 20/9/2007 | Phase IIIB Subcutaneous Missed Dose Study | A Phase IIIb, Multi-Center, Randomized, Withdrawal Study to Evaluate the Immunogenicity and Safety of Subcutaneous Administered Abatacept in Adults With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Abatacept;Drug: Placebo | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 270 | Phase 3 | United States;Argentina;Canada;Mexico;South Africa;Brazil |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT00420199 (ClinicalTrials.gov) | May 2007 | 8/1/2007 | A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate | A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate | Active Rheumatoid Arthritis | Drug: Abatacept;Drug: Placebo | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 50 | Phase 3 | Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;Austria |
| 47 | NCT00989235 (ClinicalTrials.gov) | April 2007 | 2/10/2009 | Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis | A Phase 3B, Multi-Center, Randomized, Double-blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate-naïve Early Erosive Rheumatoid Arthritis Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate - Low Dose Sub-Study | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 108 | Phase 3 | NULL |
| 48 | NCT00409838 (ClinicalTrials.gov) | April 2007 | 8/12/2006 | A Phase III Study of Abatacept in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate | A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept Administered Intravenously in Korean Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate | Rheumatoid Arthritis | Drug: Abatacept;Drug: Methotrexate;Drug: Placebo | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 113 | Phase 3 | Korea, Republic of |
| 49 | NCT00484289 (ClinicalTrials.gov) | December 2006 | 7/6/2007 | A Phase III Study of Abatacept in Japanese Subjects With Rheumatoid Arthritis | A Phase III, Multi-center, Open-label, Uncontrolled, Long-term Study to Evaluate the Safety of Abatacept (BMS-188667) in Japanese Subjects With Rheumatoid Arthritis Having Completed Clinical Studies IM101-071, IM101-034, and Also Special DMARD Failures | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 20 Years | N/A | All | 217 | Phase 3 | Japan |
| 50 | NCT00345748 (ClinicalTrials.gov) | June 2006 | 23/6/2006 | A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate | A Phase II, Multi-center, Randomized, Double-Blind, Placebo Controlled, Dose Response Study to Evaluate the Safety and Efficacy of Two Different Doses of Abatacept (BMS-188667) Administered Intravenously to Japanese Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate | Rheumatoid Arthritis | Drug: Abatacept;Drug: Placebo | Bristol-Myers Squibb | NULL | Completed | 20 Years | N/A | Both | 194 | Phase 2 | Japan |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT00254293 (ClinicalTrials.gov) | January 2006 | 15/11/2005 | Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA) | A Study to Assess the Steady-State Trough Serum Concentration, Safety, and Immunogenicity of Abatacept (BMS-188667) Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Who Are Receiving Disease Modifying Ant-Rheumatic Drugs (DMARDs) | Rheumatoid Arthritis | Drug: Abatacept or Placebo (both as IV & SC Solution);Drug: Abatacept or Placebo (both as IV & SC solution);Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 87 | Phase 1;Phase 2 | United States |
| 52 | NCT00122382 (ClinicalTrials.gov) | July 2005 | 19/7/2005 | Remission and Joint Damage Progression in Early Rheumatoid Arthritis | A Phase IIIB Multi-center, Randomized, Double-Blind Study to Evaluate Remission and Joint Damage Progression in Methotrexate Naive Early Erosive RA Subjects Treated With Abatacept Plus Methotrexate Compared With Methotrexate | Rheumatoid Arthritis | Drug: Abatacept;Drug: placebo;Drug: methotrexate | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 1052 | Phase 3 | United States;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;South Africa;Spain;United Kingdom;Austria;Ireland |
| 53 | NCT00124982 (ClinicalTrials.gov) | April 2005 | 30/6/2005 | Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy | A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options | Rheumatoid Arthritis | Drug: Abatacept;Drug: Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD);Drug: Anti-Tumor Necrosing Factor (TNF) Therapy | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 1286 | Phase 3 | United States;Belgium;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;Canada |
| 54 | NCT00095147 (ClinicalTrials.gov) | February 2005 | 1/11/2004 | Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis | A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate | Rheumatoid Arthritis | Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB);Drug: Infliximab (INF) + MTX, DB;Drug: Placebo (PLA) + MTX, DB;Drug: PLA + MTX switched to ABA+ MTX, DB;Drug: ABA, open-label (OL) | Bristol-Myers Squibb | NULL | Completed | 18 Years | 75 Years | All | 431 | Phase 3 | United States;Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland |
| 55 | NCT00124449 (ClinicalTrials.gov) | February 2005 | 30/6/2005 | Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients | A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA | Arthritis, Rheumatoid | Drug: Abatacept;Drug: placebo | Bristol-Myers Squibb | NULL | Completed | 18 Years | 75 Years | All | 56 | Phase 2 | United States;Australia;Belgium;France;Germany;Italy;Mexico;Puerto Rico;Spain;United Kingdom |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT00279734 (ClinicalTrials.gov) | August 2004 | 19/1/2006 | Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers | An Exploratory Study to Evaluate the Effect of Abatacept (BMS-188667) on the Antibody Response Following Tetanus Toxoid and 23-Valent Pneumococcal Vaccinations in Healthy Subjects | Rheumatoid Arthritis | Drug: Tetanus + pnemococcal vaccines alone;Drug: Abatacept + vaccines;Drug: Abatacept + Vaccines | Bristol-Myers Squibb | NULL | Completed | 18 Years | 65 Years | Both | 80 | Phase 1 | United States |
| 57 | NCT00095173 (ClinicalTrials.gov) | December 2003 | 1/11/2004 | BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis | A Phase III, Multi-Center, Multi-National, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of BMS-188667 in Children and Adolescents With Active Polyarticular Juvenile Rheumatoid Arthritis (JRA) | Juvenile Rheumatoid Arthritis | Drug: Abatacept;Drug: Placebo | Bristol-Myers Squibb | NULL | Completed | 6 Years | 17 Years | All | 214 | Phase 3 | United States;Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland |
| 58 | NCT00162201 (ClinicalTrials.gov) | October 2003 | 9/9/2005 | An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy | An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 16 | Phase 1 | United Kingdom |
| 59 | NCT00048581 (ClinicalTrials.gov) | December 2002 | 2/11/2002 | Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. | A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 in Subjects With Active Rheumatoid Arthritis on Background Disease Modifying Anti-Rheumatic Drugs (DMARDS) Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy | Rheumatoid Arthritis | Drug: Abatacept;Drug: Placebo | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 738 | Phase 3 | United States |
| 60 | NCT00048568 (ClinicalTrials.gov) | December 2002 | 2/11/2002 | A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate | A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate Versus Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate | Rheumatoid Arthritis | Drug: Abatacept;Drug: Methotrexate;Drug: Placebo | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 1250 | Phase 3 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | NCT00162279 (ClinicalTrials.gov) | October 2000 | 9/9/2005 | The Study of Abatacept in Combination With Etanercept | A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Intravenous Infusions of BMS-188667 (10 mg/kg) Given Monthly in Combination With Subcutaneous Injections of Etanercept (25mg)Given Twice Weekly to Subjects With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | Both | 141 | Phase 2 | United States |
| 62 | NCT00162266 (ClinicalTrials.gov) | October 2000 | 9/9/2005 | Abatacept With Methotrexate- Phase IIB | A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Two Different Doses of BMS-188667 Administered Intravenously to Subjects With Active Rheumatoid Arthritis While Receiving Methotrexate | Rheumatoid Arthritis | Drug: Abatacept (BMS-188667);Drug: Placebo | Bristol-Myers Squibb | NULL | Completed | 18 Years | N/A | All | 524 | Phase 2 | United States;Argentina;Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;South Africa;United Kingdom |
| 63 | NCT00279760 (ClinicalTrials.gov) | January 2000 | 18/1/2006 | Phase I/II Multiple-Dose LEA29Y vs CTLAG4Ig vs Placebo in Rheumatoid Arthritis | A Pilot, Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Preliminary Clinical Activity and Immunogenicity of Multiple Doses of LEA29Y and CTLA4Ig Administered Intravenously to Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Belatacept;Drug: Abatacept | Bristol-Myers Squibb | NULL | Completed | 18 Years | 65 Years | Both | 210 | Phase 1;Phase 2 | United States;Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom |